HERCRNA Trademark

Trademark Overview


On Thursday, June 9, 2022, a trademark application was filed for HERCRNA with the United States Patent and Trademark Office. The USPTO has given the HERCRNA trademark a serial number of 97450050. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Wednesday, July 30, 2025. This trademark is owned by Esperovax, Inc.. The HERCRNA trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines; Modified cells for medical or clinical use; Pharmaceuticals for the prevention or treatment of COVID19; Pharmaceuticals for the prevention or treatment of infection with respiratory syncytial virus (RSV); Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing infection, disease, or disorders; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for treating infection, disease, or disorders; mRNA-based therapeutics and therapeutic age...
hercrna

General Information


Serial Number97450050
Word MarkHERCRNA
Filing DateThursday, June 9, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateWednesday, July 30, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 5, 2023

Trademark Statements


Goods and ServicesVaccines; Modified cells for medical or clinical use; Pharmaceuticals for the prevention or treatment of COVID19; Pharmaceuticals for the prevention or treatment of infection with respiratory syncytial virus (RSV); Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing infection, disease, or disorders; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for treating infection, disease, or disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention of infection, disease, or disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of infection, disease, or disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 21, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEsperovax, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPlymouth, MI 48170

Party NameEsperovax, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPlymouth, MI 48170

Trademark Events


Event DateEvent Description
Sunday, April 2, 2023NON-FINAL ACTION E-MAILED
Monday, June 13, 2022NEW APPLICATION ENTERED
Tuesday, June 21, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 23, 2023ASSIGNED TO EXAMINER
Sunday, April 2, 2023NON-FINAL ACTION WRITTEN
Sunday, April 2, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, July 1, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Saturday, July 1, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, October 2, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, October 2, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 25, 2023ASSIGNED TO EXAMINER
Wednesday, October 25, 2023ASSIGNED TO EXAMINER
Thursday, November 2, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 5, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 5, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 30, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 30, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 30, 2024SOU EXTENSION 1 GRANTED
Tuesday, July 30, 2024SOU EXTENSION 1 FILED
Wednesday, January 29, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, January 29, 2025SOU EXTENSION 2 FILED
Thursday, January 30, 2025SOU EXTENSION 2 GRANTED
Wednesday, July 30, 2025SOU EXTENSION 3 FILED
Wednesday, July 30, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, July 30, 2025SOU EXTENSION 3 GRANTED
Wednesday, July 30, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 30, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED